Insight - Innovation - Access - Engagement - Partnering
The one summit which brings together a high level, by-invitation, boutique gathering of key innovators and decision-makers from all key stakeholder groups in digital health, tech and A.I. for neurosciences and mental health. Addressing not only opportunities but also the core challenges facing companies and stakeholders. Sharing models, lessons learned, mistakes, solutions, ways forward and best practices. Fostering a unique level of sustained high-quality discussion, access, engagement and partnering in a truly curated summit unlike any other event.
Engage the full value chain to disrupt silos and curate highly interactive, multi-disciplinary, cross-industry, and multi-stakeholder discussions of opportunities, challenges, hurdles and ways forward.
Drive transformational connections, discussion and partnering for startups and growth companies.
Deliver insight, access, engagement and partnering to foster innovation and accelerate value creation.
Contribute to meaningful improvement in healthcare outcomes and positive impact for patients and society.
From A.I. enabled drug discovery and development, big data, digital biomarkers, Real World Data and trial design, to advanced imaging, companion digital health, cognitive behavioral therapy and connected health, to neuromodulation and V.R., the pace of innovation is unprecedented.
Paradigms are changing, and the potential for positive impact on patient outcomes and quality of life, improved delivery of care, healthcare expenditure, and societal benefit are enormous.
The Neuro, Digital & A.I. Innovation Summit is organized by Broadreach Global and Hosted by the Champalimaud Foundation, with Partners the European Brain Council (EBC), and the support of our Global Innovation Partners and other key stakeholder organizations.
The launch edition in 2022 delivered a unique, meaningful and high-impact initiative unlike other events. Join us in 2023.
We are honored to introduce our advisory board: meet them in person at the summit.
Director of Neuroscience & Principal Investigator, Champalimaud Foundation
CEO & Co-Founder, Neuroelectrics
CEO/Founder - Health Innovation Partners, Angel - What if Ventures, Mentor - Amazon Web Services Healthcare Accelerator, Mentor - Texas Medical Center Innovation
Director General - Human Brain Project, and CEO - EBRAINS
Harris Eyre MD PhD
Brain Capital Builder, Lead - Brain Capital Alliance, Co lead - OECD Neuroscience-inspired Policy Initiative, Fellow - The Baker Institute for Public Policy, Senior Fellow - Meadows Mental Health Policy Institute
Digital Health & Corporate Innovation Executive, ex BMS Global Head of Digital Strategy, ex-Novartis BIOME & Open Innovation co-founder
Chairperson, Monument Therapeutics
Co-Founder/Director, Applied Neuroscience Association
Executive Director, European Brain Council (EBF)
Proudly presenting leading speakers from across the sector
Joachim Scholpp, Global Head Translational Medicine, CNS, Retinal Health & Emerging Areas, Boehringer Ingelheim
Pawel Swieboda, Director General - Human Brain Project, and CEO - EBRAINS
Ana Maicques, CEO & Co-Founder, Neuroelectrics
Beth Wolff, Director Digital Health Solutions, BD&L Search & Assessment, Lundbeck A/S
Karl Hess, Managing Director, Outcome Capital
Pamela Tenaerts, Chief Scientific Officer, Medable (to be confirmed)
Nick Taptiklis, Head of Technology Strategy, Cambridge Cognition (to be confirmed)
Chairperson, Monument Therapeutics
John Krakauer, Professor of Neurology, Neuroscience, and Physical Medicine & Rehabilitation, Johns Hopkins School of Medicine
Shwen Gwee, Digital Health & Corporate Innovation Executive, ex BMS Global Head of Digital Strategy, ex-Novartis BIOME & Open Innovation co-founder
Vreni Schoenenberger, Global Franchise Head, External Affairs /Partnership Strategy, Novartis (to be confirmed)
J.P. Borges Managing Partner, JP Borges Abogados, Co-Founder Exputnik Accelerator
Maneesh Juneja, Digital Health Futurist (to be confirmed)
Christian J. Suojanen, CEO - Broadreach Global, Member of the Executive Board - European Brain Foundation
Two days of sustained, interactive discussion, networking and partnering with:
Founders & CEOs
Key Opinion Leaders
From startup and growth companies at the confluence of neuroscience and mental health with digital, medtech, imaging, technology, data and A.I.
Senior industry executives from pharma, digital health, technology & health providers & systems. Heads of therapeutic area, R&D, real world data, clinical development, digital health, scouting, business development & licensing.
In CNS, neuroscience and mental health, data, health tech, digital health, A.I. and deeptech.
VC and corporate venture, private equity, family offices, angels & HNW.
Key Opinion Leaders from all stakeholder groups at the confluence of neurosciences & mental health with digital, technology, data and A.I.
Government & NGOs
Public agencies, societies, associations & NGOs in brain health, neurology, neurosciences, psychiatry & mental health, patient organizations, economic development, health, research & innovation.
A selected group of leading specialized advisors and consultants with deep subject matter expertise relevant to participants.
Detailed program coming soon.
Topics and themes include:
Calling neuroscience, mental health, technology, data, digital health and A.I. innovation-leaders, decision-makers & KOLs, from all stakeholder groups; join in an open format, high-engagement, silo-bridging, cross industry, multi-disciplinary summit of interactive discussions on rising to both the challenges and the opportunities in brain health innovation:
The scope of the problem & unmet medical need
Dementia & neurodegeneration
Traumatic & non-traumatic brain injury
Data, Technology & A.I. in precision medicine & drug development
Real World Data & distributed, technology clinical trials
Digital biomarkers, surrogate & clinical end points
Digital delivery of care & C.B.T.
Monitoring, early detection & diagnosis
Wearables, sensors & connected health
Digital tools, medicines & therapeutics
Companion digital health or alternative (digital) care journey
Deep brain implants & machine brain interface
Tackling issues and challenges including:
What treatment paradigms and business models hold real promise?
Where are the real challenges?
What is needed to define the way forward?
Regulatory & I.P. issues
Pricing & reimbursement
The startup journey, path to market & recurring pitfalls.
Health system compatibility.
Proof of Concept to workflow integration & first use case.
Market entry & penetration.
Partnering, licensing & collaboration.
Getting to scale.
Av. Brasília, 1400-038
The Champalimaud Foundation carries out research in cutting-edge fields and strives to stimulate discoveries that benefit people, and to promote new standards of knowledge.
It is at the Champalimaud Centre for the Unknown, in Lisbon, that the Foundation develops its activity in the areas of neuroscience and cancer. This is done through both research programmes and the provision of clinical services of excellence. It also has an outreach programme to fight blindness.
To pursue its objectives in achieving significant scientific advances, the Champalimaud Foundation adopts a translational methodology, which establishes a direct link and interdependency between basic research and clinical activity. This is a fundamental part of the Foundation’s methodology.
Ultimately, the Champalimaud Foundation aims to promote the health and well-being of humankind by seeking to actively participate in the search for solutions that can alleviate the burden of disease on societies and individuals.
GET IN TOUCH
Reach us here if you like to
Nominate a speaker
Apply to present your company or technology
Enquire about sponsorship & exhibition opportunities
Be the first to know
Subscribe and be among the first to receive all updates, announcements and invitations